May 10, 2022
Non-Clinical Safety Considerations when Developing Targeted Protein Degraders
Applied Pharmaceutical Toxicology (APT) 2022
Read More
May 3, 2022
Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
May 3, 2022
STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More
April 27, 2022
Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine
2nd Annual Ligase Targeting Drug Development Summit
Read More
April 26, 2022
Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics
2nd Annual Ligase Targeting Drug Development Summit
Read More
April 7, 2022
KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
American Association for Cancer Research Annual Meeting
Other
Read More
December 13, 2021
Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
The 63rd Annual ASH Meeting and Exposition
Other
Read More
December 13, 2021
A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
The 63rd Annual ASH Meeting and Exposition
Other
Read More
November 12, 2021
Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition
SITC 2021
Other
Read More
October 28, 2021
Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets
4th Annual TPD Summit
Read More